DR

Dhiraj Raghuvanshi

Director Director DIN 09232897
DIN 09232897 First appointment Jul 2021 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Jul 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Dhiraj Raghuvanshi

Data last updated:

Dhiraj Raghuvanshi was a Director at Epcure Pharmalab Private Limited (2021–2023) and Director at Biovyt Pharma Private Limited (from 2021). The companies operate in Pharma.

DIN 09232897
Primary Designation Director
Industry Pharma
First Appointment 09 Jul 2021
Oldest Company Age 5 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Epcure Pharmalab Private Limited U51909MP2019PTC048441
Director09 Jul 20212019₹2.91 Cr (FY 2022)Active
Biovyt Pharma Private Limited U24290MP2021PTC057549
Director21 Sep 20212021Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Biovyt Pharma Private Limited
Epcure Pharmalab Private Limited
Premium access

Shareholding and investment profile for Dhiraj Raghuvanshi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dhiraj Raghuvanshi

Dhiraj Raghuvanshi was first appointed on 09 Jul 2021 as Director at Epcure Pharmalab Private Limited.

Dhiraj Raghuvanshi held 2 earlier board appointments: Epcure Pharmalab Private Limited (Director, 09 Jul 2021 to 27 Apr 2023); Biovyt Pharma Private Limited (Director, from 21 Sep 2021).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available